The Alzheimer’s Blueprint: Dr Alison Goate and Her Team’s Genetic Breakthrough

From ageing to biology - a shift 

For much of the 20^th century Alzheimer’s disease (AD) was poorly understood. The condition was long considered to be an age-related illness. However, this understanding was limited; scientists did not understand the causes and mechanisms of this disease. Much of early understanding was based on post-mortem studies of the brain (Selkoe & Hardy, 2016) meaning researchers were only looking at the end stages of the disease and rather than how it progressed. This view began to shift, as genetics transformed the way scientists approached Alzheimer’s. A key discovery would change the direction of the research, shaping how the disease is understood today. In this blog, I explore how a key genetic discovery transformed our understanding of Alzheimer’s disease, and the impact of Dr Alison Goate's work on modern neuroscience. 

Uncovering the genetic cause 

In 1991, Dr Goate and colleagues were researching AD and the underpinning mechanisms that defined it. They drew a focus on familial (early-onset) Alzheimer’s, in doing so the team identified a point mutation in the Amyloid beta Precursor Protein (APP) in families affected by early-onset AD. Unlike the better-known later onset of the disease, these causes appeared across generations of families, therefore pointing Dr Goate and her team towards a genetic cause.

The APP gene, located on chromosome 21, essentially provides instructions for producing the APP protein that is found in the brain. The APP gene itself is responsible for normal brain cell communication and maintenance, and is especially crucial for brain development. Under normal conditions this protein would be broken down in a harmless manner. However, this identified mutation altered the normal processing of the APP protein, leading to the production of Amyloid-beta which can accumulate and form small plaques which are made of peptides of Amyloid-ß, on the brain. These plaques are a defining feature of AD and are associated with the progressive memory loss and cognitive decline which is experienced by Alzheimer's patients.

This discovery provided some of the first direct evidence that AD could be caused by a genetic component, rather than being an inevitable consequence of aging in the general population (Goate et al. 1991).

How one discovery reshaped research 

This helped to pave the way for the Amyloid Hypothesis (Hardy & Higgins, 1992). The hypothesis proposes that accumulation of amyloid-beta plaques is an early and central event in AD. Although it remains debated, the model links amyloid-β build-up to tau tangles, nerve cell death, and ultimately cognitive decline. Dr Goate and her team’s findings provided the foundational genetic evidence that strengthened this framework. They confirmed APP encodes the precursor of amyloid-β, and mutations in APP can initiate amyloid deposition observed in patients’ brains.

This ‘smoking gun’ shifted the direction of subsequent research and encouraged efforts to target amyloid pathways therapeutically. Researchers identified enzymes that cut APP into the amyloid plaques, and developed BACE inhibitors intended at reducing production of amyloid-beta. Diagnostic breakthroughs (because of this hypothesis), including advances in brain imaging and biomarker detection such as PET scans, accelerated the ability to detect earlier amyloid changes, meaning high-risk individuals were identified years before symptoms developed allowing for earlier intervention.

Why this discovery still matters

Decades later this discovery remains highly influential in Alzheimer’s research. The Amyloid hypothesis, which emerged after these findings, is still a dominant framework in this field (Selkoe & Hardy, 2016). Many drug studies and development efforts focus on preventing plaque accumulation, and Amyloid-beta reduction, including antibody based treatments such as Bapineuzumab. This continued focus highlights the extent to which amyloid-based mechanisms shape research into AD today. While the discovery led the way for modern research into this disease, the framework and hypothesis are heavily debated. Some scientists in the field argue that the amyloid process is a byproduct of the disease, as some individuals who have plaques present do not develop AD. Another argument found is that some targeted treatments that were developed because of the findings, such as Bapineuzumab, haven’t been successful in reducing or mitigating symptoms such as cognitive decline, leading to the discontinuation of these treatments following unsuccessful trials.

The scientist behind the discovery 

Behind these developments is Dr Alison Goate. She is a Geneticist who completed her undergraduate degree in biochemistry at the University of Bristol, before undertaking a DPhil at the University of Oxford, where she then completed three postdoctoral fellowships. She later held a professorship at Washington University School of Medicine, working across genetics and neurology. She is currently the director of the Loeb Centre for Alzheimer's Disease and chair of the department of genetics and genomic sciences at Icahn School of Medicine, at Mount Sinai.

Beyond this initial discovery, Alison Goate has had continued involvement in identifying the genetic causes of neurodegenerative diseases including AD and Frontotemporal dementia (FTD). Her work expanded to broader genetic risk factors, such as identifying new risk genes such as TREM2. These contributions have allowed for a deeper understanding of the mechanisms of Alzheimer’s disease.

Reflecting on her career, Goate notes, “I do think that as a man I would probably have received invites earlier in my career”.

She also notes that during this time, powerful men in the field sponsored her by putting her name forward for conferences and talks. This support played a vital role in increasing her visibility within the field, particularly at a stage when recognition is critical for career progression. At the same time, it highlights persistent disparities women face in recognition within science, where male peers receive more recommendations and recognition for the work they do. It supports the challenges that many women face particularly early on in their careers to establish themselves in the field, become principal investigators and take on leadership roles. Experiences such as this shape not only individual careers, but also who is seen, heard and advanced within the field. 

As someone entering this field, and as a relative of Dr Alison Goate, this perspective highlights how career progression depends not only on scientific ability, but having equal access to opportunities, mentorship and support from others. Her work has not only shaped this field, but has also influenced my own interest in pursuing a career in science, through conversations about research over the years. 

Breaking barriers in neuroscience 

Her experience reflects broader patterns within neuroscience. While increasing numbers of women are entering the field, representation in senior roles remains limited. Goate emphasises that mentorship and sponsorship play a critical role in shaping career progression. Fewer opportunities for women creates barriers to career development and progression into leadership roles. Although progress has been made, her experience highlights the importance of continued support and visibility for women in neuroscience.

Looking ahead 

Decades on, Alzheimer’s disease is no longer seen as a consequence of ageing, but as a complex neurodegenerative condition shaped by genetic processes. The discovery of mutations in the APP gene served as a turning point, helping guide research in the following years. Through her work, Dr Alison Goate has played a key role in shaping how scientists understand these diseases. As research evolves her contributions remain central to efforts in understanding the disease and development of treatments.

References:

• Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L. and Mant, R., 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349(6311), pp.704-706.

• Hardy, J.A. and Higgins, G.A., 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science, 256(5054), pp.184-185.

• Selkoe, D.J. and Hardy, J., 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine, 8(6), pp.595-608.

 ............................................................................................................................................................  

This article was written by Élise Goate and edited by Clarise Castleman, with graphics produced by Suzana Sultan. If you enjoyed this article, be the first to be notified about new posts by signing up to become a WiNUK member (top right of this page)! Interested in writing for WiNUK yourself? Contact us through the blog page and the editors will be in touch.